Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | In 2019, Ed Tate, Roberto Solari and Andrew Bell founded Myricx Bio to discover and develop a completely novel class of antibody-drug conjugates (ADCs), based on their CRUK-funded research into N-myristoyltransferase (NMT).
Less than five years later, Myricx closed its Series A financing round after raising £90m, including investment from Cancer Research Horizons.
The team’s breakthrough was discovering the potential of NMT inhibitors to treat cancer and they have since demonstrated their efficacy as a completely new class of ADC. Currently, over 90% of clinical ADCs are based on only three mechanisms. Diversifying the pipeline will offer more treatment options to people who respond poorly to well-known payloads. |
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
|
| | |
|
|
New in Nature Genetics: Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer |
| Marnix Jansen and colleagues at the UCL Cancer Institute and University Medical Center Utrecht published research in Nature Genetics last week, providing insight into how mismatch repair-deficient (MMRd) colorectal cancers use genetic switches to adapt mutation rates and evade the immune system.
The study which we co-funded, analysed whole genome sequences from 217 MMRd colorectal cancer samples in the 100,000 Genomes Project database, looking for links between the number of mutations and genetic changes in key DNA repair genes. The team identified that MSH6 and MSH3 homopolymers act as evolvability switches, altering mutation rate and mutation bias in response to immune selection to drive rapid exploration of immune escape solutions. |
| | |
|
|
|
| | | | Congratulations to Owen Sansom, director at our Cancer Research UK Scotland Institute, who has been elected to EMBO Membership. This recognises Owen’s research excellence and outstanding achievements in the life sciences.
To celebrate EMBO’s 60th anniversary, over 100 leading researchers from Europe and around the world have been elected this year.
EMBO members guide the execution of programmes and activities by evaluating funding applications and contributing to training, policy, outreach and mentorship initiatives. | | |
| | | | | | Edith is a world-leader in genetics, epigenetics and development biology. She currently leads EMBL and has held roles at the College de France and the Institut Curie.
Edith received her PhD from the Imperial Cancer Research Fund, one of the constituent organisations of the Francis Crick Institute.
Edith will take up the position from summer 2025, taking over from Sir Paul Nurse, the Crick’s founding director and chief executive. | | |
|
|---|
|
|
|
|
| | The many adventures of a promising ADC |
| | It’s a winding path to successful clinical development, and Ed Tate, Myricx Bio co-founder and chair of its Scientific Advisory Board, knows that only too well.
As Myricx celebrates a £90m investment, we’ve interviewed Ed about founding the company and its approach to developing first-in-class N-myristoyltransferase (NMT) inhibitors as antibody-drug conjugate (ADC) payloads.
We spoke to Ed to find out how they put their ADC on the path to clinical development – a journey taking in obscure enzymes, malaria and even the common cold… |
| | |
|
|
|---|
|
|
|
|
|
| | Success in Boston, next stop London – save the date for our Cancer Prevention Research Conference |
| The second annual Cancer Prevention Research Conference is taking place in London from 25–27 June 2025. This follows the sold out first event in Boston where over 350 attendees from all over the world had the opportunity to engage and discuss the latest concepts in cancer prevention research.
This year’s event will be hosted by Cancer Research UK, in collaboration with the American Cancer Society. Mark the date in your calendars and register your interest to be amongst the first to hear when registrations open. |
| | |
| | |
|
|
|
|
What did you think of this email? |
|
| | |
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | You are playing a crucial role in helping us beat cancer sooner, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
